Formycon AG announced that it appointed Bernhard Hampl to the Advisory Board. Over the past 20 years, Dr. Bernhard Hampl was CEO in large American generics companies such as EON LABS Inc. and later Sandoz US. He advises companies from the field of pharmaceuticals and biotechnology as well as investment companies.
Market Closed -
Other stock markets
|
After market 10:32:55 pm | |||
43.75 EUR | -1.24% | 44.05 | +0.69% |
25/04 | Formycon AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
18/03 | Formycon, Fresenius Kabi Sign Settlement Deal with Johnson & Johnson for Ustekinumab Biosimilar | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.43% | 85Cr | |
+43.53% | 5.09TCr | |
-0.51% | 4.21TCr | |
+49.62% | 4.2TCr | |
-7.20% | 2.92TCr | |
+13.21% | 2.6TCr | |
-21.93% | 1.89TCr | |
+7.68% | 1.32TCr | |
+24.07% | 1.22TCr | |
+30.15% | 1.22TCr |
- Stock Market
- Equities
- FYB Stock
- News Formycon AG
- Formycon AG Appoints Bernhard Hampl to the Advisory Board